Modality
mAb
MOA
CGRPant
Target
PD-L1
Pathway
Lipid Met
AngelmanWM
Development Pipeline
Preclinical
~Oct 2013
→ ~Jan 2015
Phase 1
~Apr 2015
→ ~Jul 2016
Phase 2
~Oct 2016
→ ~Jan 2018
Phase 3
~Apr 2018
→ ~Jul 2019
NDA/BLA
~Oct 2019
→ ~Jan 2021
Approved
Apr 2021
→ Oct 2029
ApprovedCurrent
NCT05722673
1,044 pts·WM
2021-09→TBD·Active
NCT05614414
2,672 pts·Angelman
2021-04→2029-10·Recruiting
NCT08526605
467 pts·WM
2024-10→2027-05·Completed
+1 more trial
6,981 total pts2 indications
CompletedCurrentUpcoming
Catalysts (2)
2027-05-251.1y awayPh3 Readout· WM
2029-10-243.6y awayPh3 Readout· Angelman
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
Approved
Recruit…
Approved
Active
Approved
Complet…
Approved
Complet…
Catalysts
Ph3 Readout
2027-05-25 · 1.1y away
WM
Ph3 Readout
2029-10-24 · 3.6y away
Angelman
RecruitingActiveCompleted|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05722673 | Approved | WM | Active | 1044 | DOR |
| NCT05614414 | Approved | Angelman | Recruiting | 2672 | PFS |
| NCT08526605 | Approved | WM | Completed | 467 | VA |
| NCT06966819 | Approved | WM | Completed | 2798 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| INC-2432 | Incyte | Phase 2 | CD47 | |
| Sematapinarof | Legend Biotech | NDA/BLA | VEGF |